Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN® in Non-Small Cell Lung Cancer

Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Study 
of REOLYSIN® in Non-Small Cell Lung Cancer 
CALGARY, March 5, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") 
(TSX:ONC) (NASDAQ:ONCY) today announced that it has completed patient 
enrollment in a Phase 2 clinical trial evaluating intravenous administration 
of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients 
with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours 
(REO 016). 
This trial is a single arm, single-stage, open-label, Phase 2 study of 
REOLYSIN given intravenously with paclitaxel and carboplatin every three 
weeks. Patients received four to six cycles of paclitaxel and carboplatin in 
conjunction with REOLYSIN, following which REOLYSIN could be continued as a 
monotherapy. 
Eligible patients included those with metastatic or recurrent NSCLC with Kras 
or EGFR-activated tumours, who had not received chemotherapy treatment for 
their metastatic or recurrent disease. Patients must have demonstrated 
mutations in Kras or EGFR, or EGFR gene amplification in their tumours 
(metastatic or primary) in order to qualify for the trial. 
The Company previously reported in November 2012 that 33 patients had received 
Reovirus (REOLYSIN) (3 x 10(10) TCID(50)) intravenously daily on days one to 
five, in combination with carboplatin and paclitaxel. Molecular tumor 
demographics included: 16 Kras, three EGFR, four BRAF mutations, and 10 EGFR 
amplified only. Response evaluation data reported among 30 evaluable patients 
showed 27 patients had stable disease or better for a 90% clinical benefit 
rate (nine partial response (PR) (30%) and 18 stable disease (SD) (60%)). 
Three patients had progressive disease (PD) as their best response. 
"We have seen encouraging results in both this and other trials looking at 
primary and metastatic lung disease and are continuing to push our lung 
program forward on that basis," said Dr. Brad Thompson, President and CEO of 
Oncolytics. "We have extended our work in this indication beyond this drug 
combination and are currently evaluating REOLYSIN in conjunction with 
docetaxel or pemetrexed in a second line open-label, randomized, non-blinded, 
Phase II clinical study sponsored by the NCIC Clinical Trials Group at Queen's 
University in Kingston, Ontario that will enroll up to 150 squamous cell and 
adenocarcinoma of the lung patients." 
About Oncolytics Biotech Inc. 
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. For further information about Oncolytics, please visit: 
www.oncolyticsbiotech.com. 
This press release contains forward-looking statements within the meaning of 
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act 
of 1934, as amended, and forward-looking information within the meaning of 
Canadian securities laws. Statements, other than statements of historical 
facts, included in this press release that address activities, events or 
developments that Oncolytics expects or anticipates will or may occur in the 
future, including such things as, the Company's expectations related to the 
Phase 2 non-small cell lung cancer trial of REOLYSIN in combination with 
paclitaxel and carboplatin, and the Company's belief as to the potential of 
REOLYSIN as a cancer therapeutic, and other such matters are forward-looking 
statements and forward-looking information and involve known and unknown risks 
and uncertainties, which could cause the Company's actual results to differ 
materially from those in the forward-looking statements and forward-looking 
information. Such risks and uncertainties include, among others, risks related 
to the statistical sufficiency of patient enrollment numbers in separate 
patient groups, the availability of funds and resources to pursue research and 
development projects, the efficacy of REOLYSIN as a cancer treatment, the 
tolerability of REOLYSIN outside a controlled test, the success and timely 
completion of clinical studies and trials, the Company's ability to 
successfully commercialize REOLYSIN, uncertainties related to the research and 
development of pharmaceuticals and uncertainties related to the regulatory 
process. Investors should consult the Company's quarterly and annual filings 
with the Canadian and U.S. securities commissions for additional information 
on risks and uncertainties relating to the forward-looking statement and 
forward-looking information. Investors are cautioned against placing undue 
reliance on forward-looking statements and forward-looking information. The 
Company does not undertake to update these forward-looking statements and 
forward-looking information, except as required by applicable laws. 
The Equicom Group Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta, T2P 
3C4 Tel: 403.218.2835 Fax: 403.218.2830 nhurst@tmxequicom.com 
Dian Griesel, Inc. Susan Forman 396 West Broadway, 2nd Floor New York, NY 
10012 Tel: 212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/05/c2290.html 
CO: Oncolytics Biotech Inc.
ST: Ontario
NI: BTC  
-0- Mar/05/2013 11:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.